Trends in C-reactive protein levels in US adults from 1999 to 2010

American Journal of Epidemiology

Volumn 177, Issue 12, 2013, Pages 1430-1442

  Ong, Kwok Leung ^a,b   Allison, Matthew A ^c   Cheung, Bernard M Y ^d   Wu, Ben J ^a   Barter, Philip J ^a,b   Rye, Kerry Anne ^a,b,e  

^a HEART RESEARCH INSTITUTE   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

C reactive protein; inflammation; population; risk factors

Indexed keywords

ALDOSTERONE RECEPTOR ANTAGONIST; ALDOSTERONE RECEPTOR BLOCKER; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; LIPID; UNCLASSIFIED DRUG;

ADULT; BIOMARKER; BODY MASS; CARDIOVASCULAR DISEASE; DRUG; HEALTH RISK; PROTEIN; RISK FACTOR; TREND ANALYSIS;

ADULT; AGE; ARTICLE; BODY MASS; ETHNICITY; FEMALE; GENDER; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY; UNITED STATES;

C-REACTIVE PROTEIN; INFLAMMATION; POPULATION; RISK FACTORS;

ADULT; AGE FACTORS; AGED; BILIRUBIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH BEHAVIOR; HEALTH SURVEYS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES;

UNITED STATES;

EID: 84878871280     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kws443     Document Type: Article

References (42)

1. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003; 107(3): 499-511.
2. Yudkin JS, Stehouwer CD, Emeis JJ, et al. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-978.
3. Shankar A, Li J, Nieto FJ, et al. Association between C-reactive protein level and peripheral arterial disease among US adults without cardiovascular disease, diabetes, or hypertension. Am Heart J. 2007;154(3):495-501.
4. Festa A, D'Agostino R, Howard G, et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation. 2000; 120(1):42-47.
5. Ong KL, Tso AW, Xu A, et al. Evaluation of the combined use of adiponectin and C-reactive protein levels as biomarkers for predicting the deterioration in glycaemia after a median of 5.4 years. Diabetologia. 2011;54(10):2552-2560.
6. Liuzzo G, Biasucci LM, Gallimore JR, et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 1994;331(7):417-424.
7. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279(18):1477-1482.
8. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation. 1998;97(20):2007-2011.
9. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoproteinassociated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) Study. Arch Intern Med. 2005;165(21):2479-2484.
10. KoenigW, Khuseyinova N, Baumert J, et al. Prospective study of high-sensitivity C-reactive protein as a determinant of mortality: results from the MONICA/KORA Augsburg Cohort Study, 1984-1998. Clin Chem. 2008;54(2):335-342.
11. Emerging Risk Factors CollaborationKaptoge S, Di Angelantonio E, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet. 2010;375(9709): 132-140.
12. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004; 350(14):1387-1397.
13. Laaksonen DE, Niskanen L, Nyyssönen K, et al. C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study. Eur Heart J. 2005;26(17):1783-1789.
14. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347(20):1557-1565.
15. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21): 2195-2207.
16. Ridker PM, Danielson E, Fonseca FA, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373(9670):1175-1182.
17. Rietzschel E, De Buyzere M. High-sensitive C-reactive protein: universal prognostic and causative biomarker in heart disease? Biomark Med. 2012;6(1):19-34.
18. Ridker PM. Inflammatory biomarkers and risks of myocardial infarction, stroke, diabetes, and total mortality: implications for longevity. Nutr Rev. 2007;65(12 Pt 2): 253S-259S.
19. Yang EY, Nambi V, Tang Z, et al. Clinical implications of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) in a US population insights from the ARIC (Atherosclerosis Risk in Communities) Study. J Am Coll Cardiol. 2009;54(25):2388-2395.
20. Genest J, McPherson R, Frohlich J, et al. Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol. 2009;25(10):567-579.
21. National Center for Health Statistics. National Health and Nutrition Examination Survey 1999-2010 questionnaires, datasets, and related documentation. Hyattsville, MD: Centers for Disease Control and Prevention; 2012. (http://www.cdc. gov/nchs/nhanes.htm). (Accessed June 4, 2012).
22. Ong KL, Wu BJ, Cheung BM, et al. Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis. 2011;219(2):728-733.
23. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med. 2006;354(23):2473-2483.
24. American Diabetes Association. Standards of medical care in diabetes-2010. Diabetes Care. 2010;33(1 suppl): 11S-61S.
25. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost. suppl):332S-339S.
26. Flegal KM, Carroll MD, Kit BK, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA. 2012;307(5):491-497.
27. Cheung BM, Ong KL, Cherny SS, et al. Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med. 2009;122(5):443-453.
28. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA. 2010;303(20):2043-2050.
29. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in US adults? Diabetes Care. 2008;31(1):81-86.
30. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
31. Li M, Ong KL, Tse HF, et al. Utilization of lipid lowering medications among adults in the United States 1999-2006. Atherosclerosis. 2010;208(2):456-460.
32. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-density lipoprotein cholesterol in the United States, 1999-2006. JAMA. 2009;302(19):2104-2110.
33. Lin JP, Vitek L, Schwertner HA. Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease. Clin Chem. 2010;56(10):1535-1543.
34. Hwang HJ, Lee SW, Kim SH. Relationship between bilirubin and C-reactive protein. Clin Chem Lab Med. 2011;49(11): 1823-1828.
35. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001;286(1):64-70.
36. Lee TS, Chang CC, Zhu Y, et al. Simvastatin induces heme oxygenase-1: a novel mechanism of vessel protection. Circulation. 2004;110(10):1296-1302.
37. Platt JL, Nath KA. Heme oxygenase: protective gene or Trojan horse. Nat Med. 1998;4(12):1364-1365.
38. de Sauvage Nolting PR, Kusters DM, Hutten BA, et al. Serum bilirubin levels in familial hypercholesterolemia: a new risk marker for cardiovascular disease? J Lipid Res. 2011;52(9): 1755-1759.
39. Ikonomidis I, Andreotti F, Economou E, et al. Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999; 100(8):793-798.
40. Woodward M, Lowe GD, Francis LM, et al. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2(11):1934-1940.
41. Ridker PM, Danielson E, Rifai N, et al. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48(1): 73-79.
42. Takeda T, Hoshida S, Nishino M, et al. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis. 2003;169(1):155-158.